ResearcherWenzhou Medical UniversityNo recent work listed

Jing Cai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6792-4959; OpenAlex author ID A5015354791. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper

Papers 2

MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. Co-author DOI 10.1016/j.yexmp.2019.04.012 ↗
USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. Co-author DOI 10.1016/j.bbrc.2017.03.025 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Bujian Pan · 1 shared paper, 2019 · strength 0.10
- Paper MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. DOI 10.1016/j.yexmp.2019.04.012 ↗
Wu Ji · 1 shared paper, 2019 · strength 0.10
- Paper MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. DOI 10.1016/j.yexmp.2019.04.012 ↗
Haibo Yu · 1 shared paper, 2019 · strength 0.10
- Paper MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. DOI 10.1016/j.yexmp.2019.04.012 ↗
Anwen Liu · 1 shared paper, 2017 · strength 0.08
- Paper USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. DOI 10.1016/j.bbrc.2017.03.025 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.